T-cell therapy is a form of immunotherapy that uses specially altered T cells — a part of the immune system — to fight cancer. A sample of a patient’s T cells are collected from the blood, then modified to produce special structures called chimeric antigen receptors (CARs) on their surface. When these T cells are reinfused into the patient, the new receptors enable them to latch onto a specific antigen on the patient’s tumor cells and kill them.Currently, T-cell therapy is FDA approved as standard of care for some forms of aggressive, relapsed or refractory non-Hodgkin lymphoma, including diffuse large B cell lymphoma, primary mediastinal B-cell lymphoma, high grade B-cell lymphoma, transformed follicular lymphoma, and mantle cell lymphoma. In addition, T-cell therapy is approved for patients with relapsed or refractory acute lymphoblastic leukemia up to age 25. There are also many clinical trials of T-cell therapy for other types of blood cancer and solid tumors.Download PDF Sample Report: https://www.alliedmarketresearch.com/request-sample/10893
Pharmaceutical and biotechnological companies together with governments around the globe are working to combat with the COVID-19 outbreak, from supporting the development of vaccines to schedule for medicines supply chain challenges. Furthermore, there are around 115 vaccine candidates and other 155 molecules that are kept in the R&D pipeline in the coming years. Moreover, commonly used drugs, such as hydroxychloroquine, have witnessedhugeboost in demand for the management of COVID-19. Increase in demand for drugs had presented huge opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Attributedto the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is anticipated to witness a substantial growth in the next few years.
Top impacting factors: Market scenario analysis, trends, drivers, and impact analysis
The major factor affecting the industry includesincrease inapplication of T-cell therapeutic immunity system. In addition, growth in the number of cancer patients globally would help the industry propel during the forecast period.Variation in disease patterns and the surge in awareness programs among the population are anticipated to help the industry gain traction in the next few years.Favorable reimbursement policies &strictregulations and applicability of T-cell therapies in various research centers mainly focusing on cancer treatmentare expected to boost the growth of the industry over the forecast period.
Growth in the number of products launches to boost the T-Cell therapy market
Increase in number of products launches due to high demand from the population is anticipated to propel the growth of the industry in the next few years. For instance, in July 2020, the U.S. Food and Drug Administration approved Tecartus (brexucabtagene autoleucel), a cell-based gene therapy for treatment of adult patients diagnosed with mantle cell lymphoma (MCL) who have not responded to or who have relapsed following other kinds of treatment. Tecartus, a chimeric antigen receptor (CAR) T cell therapy, is the first cell-based gene therapy approved by the FDA for the treatment of MCL.
Furthermore, in June 2019, Proteona Pte. Ltd. launched its latest ESCAPE proteogenomics assay designed specifically for Chimeric Antigen Receptor (CAR)T cell characterization. This is the first commercial product designed to characterize both RNA and protein expression levels across thousands of single CART cells. Through the use of simultaneous gene and protein expression analysis, the ESCAPE CAR T assay is able to identify CAR positive cells, measure changes in cytokine expression,deeply phenotype cells through measuring the expression of 25 key cell surface proteins, and discover new gene expression patterns important for research. Together with Proteona’s state-of-the-art data analysis support, the ESCAPE CAR T assay provides rich information that can be used at all stages of the CAR T workflow from initial cell collection to post infusion patient monitoring.
Key segments covered:
- Hematologic Malignancies
- Solid Tumors
Type of Imaging
- TCR Therapy
- CAR T-Cell Therapy
- TIL Therapy
Key benefits of the report:
- This study presents the analytical depiction of the global T-Cell therapymarketalong with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global T-Cell therapymarket share.
- The current market is quantitatively analyzed from 2020 to 2027 to highlight the global T-Cell therapymarket growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed global T-Cell therapymarket analysis based on competitive intensity and how the competition will take shape in coming years.
For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/10893
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.